Surgery News

CBio achieves recruitment milestone in XToll clinical trial

December 14, 2015

"Given that the same research path might lead to alternative treatments for diseases such as Lupus the company is now investigating what resources would be needed to start an additional program in this area," he said.

"There are a number of people who would like to see us move quickly on this path, which is not surprising given that the prospects for the alleviation of suffering as well as commercial return are impressive," Mr Yeates said.

"However, we will not divert energy from the core rheumatoid arthritis program which is now highly advanced," he said.

"Up to 2 per cent of the world's population suffer from rheumatoid arthritis and addressing that market remains the company's primary focus. If the company is to accelerate research into Lupus, then additional funding would need to be sourced. This is something the Board of Directors may want to consider at some point," Mr Yeates said.

CBio's pre-clinical research into therapeutic uses of XToll in diseases other than rheumatoid arthritis has been submitted to a number of global therapeutic conferences being held in late 2010.